Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

Status Not yet recruiting

Clinical Trial Summary

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Clinical Trial Description

Cancer of unknown primary origin (CUP) includes a cluster of heterogeneous tumors that have exceptional clinical features: it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation. The incidence of CUP ranges around 2% of all new cancer diagnoses. The work up list of CUP include; a biopsy proven malignancy, a detailed physical examination, many laboratory, radiological and endoscopy. However, these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients. In this context, positron-emission tomography (PET) combined with computed tomography (PET/CT), using the radiotracer 18F fluoro- 2-deoxyglucose (FDG) is an alternative, non-invasive imaging modality with accurate diagnostic performance. It considered good tool for diagnosis of patients with CUP . The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate. Failure to identify the primary tumor hampers optimization of management planning, which in turn may adversely influence patient prognosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06055764
Study type	Observational
Source	Assiut University
Contact	Esraa Mamdouh
Phone	+20112322029
Email	esraamamdouh22222@gmail.com
Status	Not yet recruiting
Phase
Start date	October 2023
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01441115` - ECI301 and Radiation for Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT03257722` - Pembrolizumab + Idelalisib for Lung Cancer Study	Phase 1/Phase 2
Recruiting	`NCT01201096` - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	N/A
Completed	`NCT01206530` - FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT01199822` - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors	Phase 1
Completed	`NCT00313859` - Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	Phase 2
Completed	`NCT00377936` - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas	Phase 2
Recruiting	`NCT05095207` - Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT04392479` - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.	Phase 3
Recruiting	`NCT04808466` - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Terminated	`NCT03652493` - Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway	Phase 2
Not yet recruiting	`NCT04845490` - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT05061082` - Genomic Evolution of Metastasis in Gastric Cancer
Terminated	`NCT02796729` - CEST- Glucose Enhanced MRI for Metastatic Brain Tumours	Phase 2
Withdrawn	`NCT01157039` - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin	Phase 2
Terminated	`NCT01000948` - A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer	Phase 2
Terminated	`NCT01613482` - TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention	Phase 3
Withdrawn	`NCT00244348` - Hepatic Artery Infusion With Oxaliplatin	Phase 1/Phase 2
Recruiting	`NCT04416165` - Comparison of FDG and FAPI in Patients With Various Types of Cancer	N/A
Recruiting	`NCT04617457` - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas	Phase 2